Fluoxetine Protects Retinal Ischemic Damage in Mice
暂无分享,去创建一个
C. Bucolo | V. Micale | G. L. Romano | L. Gozzo | F. Drago | S. Di Martino | O. M. Maurel | Valentina Riolo
[1] A. Grumezescu,et al. An Overview of Oxidative Stress, Neuroinflammation, and Neurodegenerative Diseases , 2022, International journal of molecular sciences.
[2] V. Uskoković,et al. Brain-Derived Neurotrophic Factor-Mediated Neuroprotection in Glaucoma: A Review of Current State of the Art , 2022, Frontiers in Pharmacology.
[3] M. Plebanski,et al. Targeting Differential Roles of Tumor Necrosis Factor Receptors as a Therapeutic Strategy for Glaucoma , 2022, Frontiers in Immunology.
[4] Y. Cai,et al. Microglia in the Neuroinflammatory Pathogenesis of Alzheimer’s Disease and Related Therapeutic Targets , 2022, Frontiers in Immunology.
[5] K. Jonak,et al. Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy: A Pilot Study , 2022, Frontiers in Pharmacology.
[6] David J. Calkins,et al. Solving neurodegeneration: common mechanisms and strategies for new treatments , 2022, Molecular Neurodegeneration.
[7] James F. Everson,et al. Modulation of microglial activation by antidepressants , 2022, Journal of psychopharmacology.
[8] R. Casson. Medical therapy for glaucoma: A review , 2022, Clinical & experimental ophthalmology.
[9] S. Salomone,et al. Antioxidant Activity of Fluoxetine and Vortioxetine in a Non-Transgenic Animal Model of Alzheimer’s Disease , 2021, Frontiers in Pharmacology.
[10] R. Maccarone,et al. Retinal ganglion cell loss in an ex vivo mouse model of optic nerve cut is prevented by curcumin treatment , 2021, Cell death discovery.
[11] Osama M. Ahmed,et al. A Review of Potential Novel Glaucoma Therapeutic Options Independent of Intraocular Pressure. , 2021, Survey of ophthalmology.
[12] C. Tovilla-Zárate,et al. Fluoxetine modulates the pro-inflammatory process of IL-6, IL-1β and TNF-α levels in individuals with depression: a systematic review and meta-analysis , 2021, Psychiatry Research.
[13] Takaaki Kuwajima,et al. Serotonin transporter-mediated molecular axis regulates regional retinal ganglion cell vulnerability and axon regeneration after nerve injury , 2021, PLoS genetics.
[14] F. Drago,et al. Health Technology Assessment of Advanced Therapy Medicinal Products: Comparison Among 3 European Countries , 2021, Frontiers in Pharmacology.
[15] A. Pascale,et al. Ocular Neurodegenerative Diseases: Interconnection between Retina and Cortical Areas , 2021, Cells.
[16] N. Vale,et al. Antidepressants in Alzheimer’s Disease: A Focus on the Role of Mirtazapine , 2021, Pharmaceuticals.
[17] E. Strettoi,et al. Lipid Nanoparticles Traverse Non-Corneal Path to Reach the Posterior Eye Segment: In Vivo Evidence , 2021, Molecules.
[18] F. Oddone,et al. Risk Factors for Retinal Ganglion Cell Distress in Glaucoma and Neuroprotective Potential Intervention , 2021, International journal of molecular sciences.
[19] F. Drago,et al. Brimonidine is Neuroprotective in Animal Paradigm of Retinal Ganglion Cell Damage , 2021, Frontiers in Pharmacology.
[20] Patrice D Smith,et al. Harnessing Astrocytes and Müller Glial Cells in the Retina for Survival and Regeneration of Retinal Ganglion Cells , 2021, Cells.
[21] J. Mollon,et al. Retinal Ganglion Cells—Diversity of Cell Types and Clinical Relevance , 2021, Frontiers in Neurology.
[22] F. Drago,et al. Influence of Trace Elements on Neurodegenerative Diseases of The Eye—The Glaucoma Model , 2021, International journal of molecular sciences.
[23] A. Ponzetto,et al. The Role of Neuroinflammation in Glaucoma: An Update on Molecular Mechanisms and New Therapeutic Options , 2021, Frontiers in Neurology.
[24] Mohamed Said Boulkrane,et al. COVID-19 Disease and Vitamin D: A Mini-Review , 2020, Frontiers in Pharmacology.
[25] G. Guidoboni,et al. Neurodegenerative Disorders of the Eye and of the Brain: A Perspective on Their Fluid-Dynamical Connections and the Potential of Mechanism-Driven Modeling , 2020, Frontiers in Neuroscience.
[26] C. Baudouin,et al. Inflammation in Glaucoma: From the back to the front of the eye, and beyond , 2020, Progress in Retinal and Eye Research.
[27] F. Jessen,et al. Depression—an underrecognized target for prevention of dementia in Alzheimer’s disease , 2020, Translational Psychiatry.
[28] Jian Liu,et al. Neuroprotective Effects of Fluoxetine Against Chronic Stress-Induced Neural Inflammation and Apoptosis: Involvement of the p38 Activity , 2020, Frontiers in Physiology.
[29] B. Kiss,et al. Redox metabolism modulation as a mechanism in SSRI toxicity and pharmacological effects , 2020, Archives of Toxicology.
[30] A. Ambrósio,et al. Neuroprotective Strategies for Retinal Ganglion Cell Degeneration: Current Status and Challenges Ahead , 2020, International journal of molecular sciences.
[31] John H. Zhang,et al. Glial Cells: Role of the Immune Response in Ischemic Stroke , 2020, Frontiers in Immunology.
[32] N. Greig,et al. Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments , 2019, Front. Cell Dev. Biol..
[33] Mouse Model , 2019, Definitions.
[34] S. Chavala,et al. Hybrid Compound SA-2 is Neuroprotective in Animal Models of Retinal Ganglion Cell Death. , 2019, Investigative ophthalmology & visual science.
[35] A. Palmeri,et al. Fluoxetine and Vortioxetine Reverse Depressive-Like Phenotype and Memory Deficits Induced by Aβ1-42 Oligomers in Mice: A Key Role of Transforming Growth Factor-β1 , 2019, Front. Pharmacol..
[36] D. Zacks,et al. Retinal neuroprotection: current strategies and future directions , 2019, Current opinion in ophthalmology.
[37] W. Cubała,et al. The Influence of Antidepressants on the Immune System , 2019, Archivum Immunologiae et Therapiae Experimentalis.
[38] F. Shi,et al. Dissemination of brain inflammation in traumatic brain injury , 2019, Cellular & Molecular Immunology.
[39] B. Jin,et al. Norfluoxetine Prevents Degeneration of Dopamine Neurons by Inhibiting Microglia-Derived Oxidative Stress in an MPTP Mouse Model of Parkinson's Disease , 2018, Mediators of inflammation.
[40] Xinghuai Sun,et al. Activation of 5-HT1A Receptors Promotes Retinal Ganglion Cell Function by Inhibiting the cAMP-PKA Pathway to Modulate Presynaptic GABA Release in Chronic Glaucoma , 2018, The Journal of Neuroscience.
[41] M. Craske,et al. The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation , 2018, Neuroscience & Biobehavioral Reviews.
[42] Machelle T. Pardue,et al. Neuroprotective strategies for retinal disease , 2018, Progress in Retinal and Eye Research.
[43] C. Nucci,et al. Neuroprotective agents in the management of glaucoma , 2018, Eye.
[44] V. Yarnykh,et al. Effects of Fluoxetine on Hippocampal Neurogenesis and Neuroprotection in the Model of Global Cerebral Ischemia in Rats , 2018, International journal of molecular sciences.
[45] V. Porciatti,et al. Anesthetic Preconditioning as Endogenous Neuroprotection in Glaucoma , 2018, International journal of molecular sciences.
[46] M. Carbonelli,et al. Patterns of Retinal Ganglion Cell Damage in Neurodegenerative Disorders: Parvocellular vs Magnocellular Degeneration in Optical Coherence Tomography Studies , 2017, Front. Neurol..
[47] M. Wagner,et al. Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer's Dementia in Individuals With Previous Depression. , 2017, The American journal of psychiatry.
[48] L. Levin,et al. Neuroprotection in Glaucoma: Animal Models and Clinical Trials. , 2017, Annual review of vision science.
[49] Jian-Zhi Wang,et al. Long-term Ameliorative Effects of the Antidepressant Fluoxetine Exposure on Cognitive Deficits in 3 × TgAD Mice , 2016, Molecular Neurobiology.
[50] F. Grus,et al. Modulation of the Immune System for the Treatment of Glaucoma , 2017, Current neuropharmacology.
[51] F. K. Ludka,et al. Atorvastatin and Fluoxetine Prevent Oxidative Stress and Mitochondrial Dysfunction Evoked by Glutamate Toxicity in Hippocampal Slices , 2017, Molecular Neurobiology.
[52] London,et al. European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 3: Treatment principles and options Supported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 3 Treatment principles and options. , 2017, The British journal of ophthalmology.
[53] P. Gass,et al. Fluoxetine reverses behavior changes in socially isolated rats: role of the hippocampal GSH-dependent defense system and proinflammatory cytokines , 2017, European Archives of Psychiatry and Clinical Neuroscience.
[54] Pete A. Williams,et al. Neuroinflammation in glaucoma: A new opportunity , 2017, Experimental eye research.
[55] Karan H. Patel,et al. Serotonin receptor 2C regulates neurite growth and is necessary for normal retinal processing of visual information , 2017, Developmental neurobiology.
[56] Jiawei Wang,et al. Melanopsin-Containing or Non-Melanopsin-Containing Retinal Ganglion Cells Response to Acute Ocular Hypertension With or Without Brain-Derived Neurotrophic Factor Neuroprotection. , 2016, Investigative ophthalmology & visual science.
[57] J. Jonas,et al. MicroRNA regulation in an animal model of acute ocular hypertension , 2016, Acta ophthalmologica.
[58] Gang Hu,et al. Fluoxetine protects against IL-1β-induced neuronal apoptosis via downregulation of p53 , 2016, Neuropharmacology.
[59] E. Duh,et al. A Mouse Model of Retinal Ischemia-Reperfusion Injury Through Elevation of Intraocular Pressure. , 2016, Journal of visualized experiments : JoVE.
[60] Y. Tizabi. Duality of Antidepressants and Neuroprotectants , 2016, Neurotoxicity Research.
[61] T. Jeitner,et al. Serotonin as a putative scavenger of hypohalous acid in the brain. , 2016, Biochimica et biophysica acta.
[62] E. Lauterbach. Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease. , 2016, American journal of neurodegenerative disease.
[63] G. Sancesario,et al. Association Between Alzheimer's Disease and Glaucoma: A Study Based on Heidelberg Retinal Tomography and Frequency Doubling Technology Perimetry , 2015, Front. Neurosci..
[64] V. Porciatti. Electrophysiological assessment of retinal ganglion cell function. , 2015, Experimental eye research.
[65] F. Drago,et al. Neuroprotective effects of the monoamine oxidase inhibitor tranylcypromine and its amide derivatives against Aβ(1-42)-induced toxicity. , 2015, European journal of pharmacology.
[66] J. Krakauer,et al. Fluoxetine Maintains a State of Heightened Responsiveness to Motor Training Early After Stroke in a Mouse Model , 2015, Stroke.
[67] C. Trentini,et al. The efficacy of long-term psychodynamic psychotherapy, fluoxetine and their combination in the outpatient treatment of depression , 2015, Psychotherapy research : journal of the Society for Psychotherapy Research.
[68] Xuan Sun,et al. Fluoxetine enhanced neurogenesis is not translated to functional outcome in stroke rats , 2015, Neuroscience Letters.
[69] L. Probert. TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects , 2015, Neuroscience.
[70] A. Corbett,et al. Increasing neurogenesis with fluoxetine, simvastatin and ascorbic Acid leads to functional recovery in ischemic stroke. , 2015, Recent patents on drug delivery & formulation.
[71] Katsunori Kobayashi,et al. Role of the 5-HT4 receptor in chronic fluoxetine treatment-induced neurogenic activity and granule cell dematuration in the dentate gyrus , 2015, Molecular Brain.
[72] T. Yune,et al. Fluoxetine prevents oligodendrocyte cell death by inhibiting microglia activation after spinal cord injury. , 2015, Journal of neurotrauma.
[73] A. Aref,et al. Senile Dementia and Glaucoma: Evidence for a Common Link , 2015, Journal of ophthalmic & vision research.
[74] M. Vidal-Sanz,et al. BDNF Rescues RGCs But Not Intrinsically Photosensitive RGCs in Ocular Hypertensive Albino Rat Retinas. , 2015, Investigative ophthalmology & visual science.
[75] J. Morris,et al. Reply to comment on “An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice” , 2014, Science Translational Medicine.
[76] Haiyun Xu,et al. Fluoxetine improves behavioral performance by suppressing the production of soluble β-amyloid in APP/PS1 mice. , 2014, Current Alzheimer research.
[77] V. Porciatti,et al. Transgenic mice expressing mutated Tyr437His human myocilin develop progressive loss of retinal ganglion cell electrical responsiveness and axonopathy with normal iop. , 2014, Investigative ophthalmology & visual science.
[78] Onkar S. Dhande,et al. Retinal ganglion cell maps in the brain: implications for visual processing , 2014, Current Opinion in Neurobiology.
[79] M. V. Cicinelli,et al. Low levels of 17-β-oestradiol, oestrone and testosterone correlate with severe evaporative dysfunctional tear syndrome in postmenopausal women: a case–control study , 2014, British Journal of Ophthalmology.
[80] Woosuk Kim,et al. Antidepressants for neuro-regeneration: from depression to Alzheimer’s disease , 2013, Archives of pharmacal research.
[81] Xiang Yang Zhang,et al. Free radicals, antioxidant defense systems, and schizophrenia , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[82] R. Vohra,et al. The role of inflammation in the pathogenesis of glaucoma. , 2013, Survey of ophthalmology.
[83] J. Hošek,et al. TNF-α signalling and inflammation: interactions between old acquaintances , 2013, Inflammation Research.
[84] Lori M. Ventura,et al. Progressive loss of retinal ganglion cell function precedes structural loss by several years in glaucoma suspects. , 2013, Investigative ophthalmology & visual science.
[85] G. Tezel. Immune regulation toward immunomodulation for neuroprotection in glaucoma. , 2013, Current opinion in pharmacology.
[86] B. Frey,et al. Preclinical and Clinical Evidence of Antioxidant Effects of Antidepressant Agents: Implications for the Pathophysiology of Major Depressive Disorder , 2012, Oxidative medicine and cellular longevity.
[87] R. Morishita,et al. Preclinical Models to Investigate Retinal Ischemia: Advances and Drawbacks , 2012, Front. Neur..
[88] P. Kaufman,et al. Advances in glaucoma treatment and management: outflow drugs. , 2012, Investigative ophthalmology & visual science.
[89] J. Goldberg,et al. Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement. , 2012, Ophthalmology.
[90] J. Winkler,et al. Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy , 2012, Experimental Neurology.
[91] M. Kahook,et al. Prevalence of Cognitive Impairment, Depression, and Anxiety Symptoms Among Older Adults With Glaucoma , 2012, Journal of glaucoma.
[92] B. Morquette,et al. The molecular basis of retinal ganglion cell death in glaucoma , 2012, Progress in Retinal and Eye Research.
[93] M. Farina,et al. Ascorbic acid treatment, similarly to fluoxetine, reverses depressive-like behavior and brain oxidative damage induced by chronic unpredictable stress. , 2012, Journal of psychiatric research.
[94] F. Drago,et al. Carbon monoxide and the eye: Implications for glaucoma therapy. , 2011, Pharmacology & therapeutics.
[95] C. Romano,et al. Agonists at the serotonin receptor (5-HT(1A)) protect the retina from severe photo-oxidative stress. , 2011, Investigative ophthalmology & visual science.
[96] M. Vidal-Sanz,et al. Brain derived neurotrophic factor maintains Brn3a expression in axotomized rat retinal ganglion cells. , 2011, Experimental eye research.
[97] M. Vetter,et al. Early microglia activation in a mouse model of chronic glaucoma , 2011, The Journal of comparative neurology.
[98] Sung‐Hwa Yoon,et al. Fluoxetine prevents LPS-induced degeneration of nigral dopaminergic neurons by inhibiting microglia-mediated oxidative stress , 2010, Brain Research.
[99] T. Connor,et al. Noradrenaline reuptake inhibitors limit neuroinflammation in rat cortex following a systemic inflammatory challenge: implications for depression and neurodegeneration. , 2009, The international journal of neuropsychopharmacology.
[100] Charles L. Raison,et al. Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression , 2009, Biological Psychiatry.
[101] E. Agardh,et al. Inflammatory Markers in Nondiabetic and Diabetic Rat Retinas Exposed to Ischemia Followed by Reperfusion , 2008, Retina.
[102] N. Sharif,et al. Serotonin receptor subtype mRNA expression in human ocular tissues, determined by RT-PCR. , 2006, Molecular vision.
[103] J. Clark,et al. What does tumour necrosis factor excess do to the immune system long term? , 2005, Annals of the rheumatic diseases.
[104] Shaoqing He,et al. Hypoxia augments TNF-alpha-mediated endothelin-1 release and cell proliferation in human optic nerve head astrocytes. , 2004, Biochemical and biophysical research communications.
[105] N. Osborne,et al. Retinal ischemia: mechanisms of damage and potential therapeutic strategies , 2004, Progress in Retinal and Eye Research.
[106] B. Aggarwal. Signalling pathways of the TNF superfamily: a double-edged sword , 2003, Nature Reviews Immunology.
[107] D. Goeddel,et al. TNF-R1 Signaling: A Beautiful Pathway , 2002, Science.
[108] S. Mohand-Said,et al. Neurodegenerative and Neuroprotective Effects of Tumor Necrosis Factor (TNF) in Retinal Ischemia: Opposite Roles of TNF Receptor 1 and TNF Receptor 2 , 2002, The Journal of Neuroscience.
[109] C. Erb,et al. High Occurrence Rate of Glaucoma among Patients with Alzheimer’s Disease , 2002, European Neurology.
[110] M. Wax,et al. TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes. , 2001, Investigative ophthalmology & visual science.
[111] M. Wax,et al. Increased Production of Tumor Necrosis Factor-a by Glial Cells Exposed to Simulated Ischemia or Elevated Hydrostatic Pressure Induces Apoptosis in Cocultured Retinal Ganglion Cells , 2000 .
[112] C. Barnstable,et al. Müller cell protection of rat retinal ganglion cells from glutamate and nitric oxide neurotoxicity. , 2000, Investigative ophthalmology & visual science.
[113] S M Podos,et al. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. , 1996, Archives of ophthalmology.
[114] Shanshan Zhao,et al. Neuroplasticity and behavioral effects of fluoxetine after experimental stroke. , 2017, Restorative neurology and neuroscience.
[115] R. Nickells,et al. Neuroinflammation in Glaucoma and Optic Nerve Damage. , 2015, Progress in molecular biology and translational science.
[116] M. Tansey,et al. TNF: a key neuroinflammatory mediator of neurotoxicity and neurodegeneration in models of Parkinson's disease. , 2011, Advances in experimental medicine and biology.
[117] M. Zueva,et al. [Molecular mechanisms of retinal ischemia]. , 2010, Vestnik oftalmologii.
[118] G. Tezel. TNF-alpha signaling in glaucomatous neurodegeneration. , 2008, Progress in brain research.
[119] R. Dantzer,et al. From inflammation to sickness and depression: when the immune system subjugates the brain , 2008, Nature Reviews Neuroscience.
[120] Haiyun Xu,et al. Dose-Related Effects of Chronic Antidepressants on Neuroprotective Proteins BDNF, Bcl-2 and Cu/Zn-SOD in Rat Hippocampus , 2003, Neuropsychopharmacology.
[121] Andreas U Bayer,et al. Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer's disease and Parkinson's disease. , 2002, American journal of ophthalmology.
[122] F. Nicoletti,et al. Mitotic signaling by beta-amyloid causes neuronal death. , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.